Cerity Partners
CPRX

Cerity Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Cerity Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$791K Sell
31,943
-548
-2% -$13.1K ﹤0.01% 1990
2025
Q4 		$758K Buy
32,491
+236
+0.7% +$5.26K ﹤0.01% 1849
2025
Q3 		$635K Buy
32,255
+3,183
+11% +$65.5K ﹤0.01% 1836
2025
Q2 		$631K Buy
29,072
+231
+0.8% +$5.45K ﹤0.01% 1751
2025
Q1 		$699K Buy
28,841
+2,359
+9% +$53.1K ﹤0.01% 1588
2024
Q4 		$548K Sell
26,482
-2,251
-8% -$48.4K ﹤0.01% 1708
2024
Q3 		$571K Buy
28,733
+6,847
+31% +$127K ﹤0.01% 1706
2024
Q2 		$339K Sell
21,886
-940
-4% -$14.6K ﹤0.01% 1754
2024
Q1 		$364K Buy
22,826
+5,595
+32% +$84.3K ﹤0.01% 1763
2023
Q4 		$290K Buy
17,231
+1,780
+12% +$24.3K ﹤0.01% 1537
2023
Q3 		$181K Buy
+15,451
New +$207K ﹤0.01% 1292
2023
Q2 		– Sell
-554
Closed -$437K – 1702
2023
Q1 		$437K Buy
+554
New +$9.14K ﹤0.01% 1352

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Cerity Partners's CPRX Position: Q1 2026 in Review

Cerity Partners reduced its Catalyst Pharmaceutical (CPRX) stake by 1.7% in Q1 2026, selling an estimated $13.1K and leaving 31,943 shares worth $791K. The position accounts for ﹤0.01% of the portfolio, ranked #1990.

Cerity Partners first reported a position in CPRX in Q1 2023 and has held it in 12 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Cerity Partners held 31,943 shares of Catalyst Pharmaceutical worth $791K as of Q1 2026.
  • Cerity Partners sold 548 Catalyst Pharmaceutical shares in Q1 2026, an estimated $13.1K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #1990 holding.
  • Cerity Partners first reported a position in Catalyst Pharmaceutical in Q1 2023 and has held it in 12 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.